Partnering As A Financing Strategy

7:45 - Networking Breakfast And Conference Registration Networking Breakfast And Conference Registration Registration Sponsored By: Sanofi Aventis

8:30 - Chairperson's Opening Remarks Troy Windt, Senior Director, Corporate Development, Upsher-Smith Chairperson's Opening Remarks Troy Windt Senior Director, Corporate Development, Upsher-Smith

8:45 - KEYNOTE PANEL: Capitalizing On M&A Opportunities To Replenish Big Pharma’s Portfolio Robert Bagdorf, Vice President Worldwide Business Development, Pfizer Ellen Lubman, Group Director, Strategic Transactions Group, Bristol-Myers Squibb Gregg Talbert, Managing Director, Corporate Finance and Investment Banking, Eli Lilly & Company Constantine Chinoporos, Vice President, Corporate Development, Genzyme Paul Darling, Principal, ZS Associates As the market continues to offer very few options for capital, many biotechs are looking at mergers and acquisitions as a much more viable solution to their cash-flow problems. This has created an opportunity for big Pharma companies to absorb biotechs with interesting assets, creating fuller pipelines. Understand how big Pharma can make the most of the situation by: Maximizing interactions with investment banks and other investment institutions to gain access to new biotechs Employing strategies to reduce risk when purchasing distressed biotechs Evaluating if the biotech is right for their corporate strategy and the economy Acquiring assets and companies without losing too much cash Robert Bagdorf Vice President Worldwide Business Development, Pfizer Robert Bagdorf, M.D., MBA, is a board-certified neurologist who joined Pfizer in 1998 in CNS Clinical Development. For the past 8 years he has held positions of increasing responsibility within business development and currently oversees licensing and acquisition external search and evaluation activities for all therapeutic areas except Oncology. Prior to joining Pfizer, Dr. Bagdorf had a large co [read more] Ellen Lubman Group Director, Strategic Transactions Group, Bristol-Myers Squibb Ellen Lubman is currently a Group Director in the Strategic Transactions Group at Bristol-Myers Squibb. Ellen focuses on M&A strategy, identification of new transaction opportunities, and initiation of “String of Pearls” transactions, as well as spearheading novel business initiatives and venture capital strategies. Prior to joining Bristol-Myers Squibb, Ellen worked with Celtic Pharma, L.P., [read more] Gregg Talbert Managing Director, Corporate Finance and Investment Banking, Eli Lilly & Company Gregg Talbert is currently Managing Director of Mergers and Acquisitions in Eli Lilly’s Corporate Finance and Investment Banking (CFIB) Group, where he leads a team responsible for executing the company’s M&A strategy. Prior to this he was a Director of M&A in CFIB. During his tenure executing M&A transactions at Lilly, Gregg and his team have played a lead role in identifying, evaluat [read more] Constantine Chinoporos Vice President, Corporate Development, Genzyme Constantine Chinoporos joined Genzyme Corporation in December 2001. He leads a team charged with the identification, evaluation, and transaction of opportunities that fit within Genzyme’s strategic intent. Prior to joining Genzyme, Constantine served in various capacities at Eli Lilly and Company over a twelve year period, including roles in Corporate Finance & Investment Banking as well as th [read more] Paul Darling Principal, ZS Associates Paul Darling is a Principal in ZS Associates' San Mateo, CA office. Paul works with emerging pharmaceutical and biotech companies as well as companies evaluating new markets for acquisition, merger, or in-licensing opportunities. He has expertise in forecasting, market opportunity assessment, commercialization, sales force strategy, incentive compensation, and operations. Paul currrently heads ZS' [read more]

9:45 - PANEL: Today’s Deals: Generating Innovative Partnering Options Mark Barrett, Director, BD, Johnson and Johnson Gordon Beck, Global Head, Drug Delivery Partnering, Roche Karen LaRochelle, Executive Director, Business Development, Bristol-Myers Squibb Paul Grayson, President and CEO, Fate Therapeutics Deal structures are always changing. What was in that deal? Why did they take that as the upfront payment? What new terms and strategies are being used? Join this panel led by senior leaders and experts and take this opportunity to learn specific strategies that have been making headlines this year: Transitioning to strategies that make use of non-cash assets Generating more flexible partnering options to create win-win partnerships Re-aligning shelved programs with strategic opportunities Mark Barrett Director, BD, Johnson and Johnson Mr. Barrett has 15 years of experience in business development, corporate strategy, and research in pharmaceutical and biotech companies and research institutions. Since 2002, he has been a member of Johnson & Johnson’s pharmaceutical business development group with responsibility for leadership and execution of global transactions including commercial and clinical stage product and company ac [read more] Gordon Beck Global Head, Drug Delivery Partnering, Roche Gordon Beck joined Roche Welwyn (UK) in 1995 within Drug Delivery Science working on the antisense collaboration with Hybridon. He then set up and led the strategic technologies team investigating key properties in oral drug absorption. In 2000 Gordon moved to Pharmaceutical R&D at Roche Nutley (USA), subsequently joining Pharma Partnering in 2004 as a Global Alliance Director. In this role he [read more] Karen LaRochelle Executive Director, Business Development, Bristol-Myers Squibb Karen is an Executive Director of Strategic Transactions at Bristol-Myers Squibb focusing on biopharmaceutical collaborations, mergers and acquisitions. Since focusing on business development in 2000, she has worked extensively in support of BMS’ worldwide commercial and R&D operations executing strategic collaborations, out-licenses and M&A spanning the oncology, antiviral and cardiovascu [read more] Paul Grayson President and CEO, Fate Therapeutics Paul Grayson is the President and CEO of Fate Therapeutics. Grayson was previously managing director of Sanderling Ventures. Over the last ten years he has completed both private and public capital fundraising, delivering more than $200 million for emerging companies. Transactions completed under Grayson’s watch produced more than $150 million in recognizable revenue with an announceable value in [read more]

10:25 - Refreshment Break And Networking Opportunity The breaks at BioNetwork are not simply an opportunity to refresh and refuel. Smart attendees use this time to discuss the ideas presented in the sessions with fellow delegates, question the speakers, and above all, network like crazy!

11:05 - PANEL: Partnering As A Strategic Tool In A Down Economy: Big Pharma Perspective Durga P. Bubba, Head, Alliance Management, Merck Vaccines and Infectious Diseases Mike Leonetti, Executive Director, Alliance Management, Boehringer-Ingelheim Stefanie A. Hansen, Director, Pharmaceutical Strategic Alliances Worldwide Business Development, Pfizer In 2008, Big Pharma accelerated critical discussions to determine the best time to partner. Today’s realities have given Big Pharma the opportunity to re-evaluate their partnering strategies to ensure they maximize asset consolidation, evaluate and partner with the most promising Biotech company, and leverage the ability to finance to their advantage. Join partnering and alliance management experts Mike Leonetti, Mark Coflin and Stefanie Hansen as they share insights and important strategies about partnering in a down economy. Outlining key drivers for successful Big Pharma-Biotech collaborations Demonstrating new approaches and strategies for value-creation in today's economy Highlighting best practices, lessons learned and models for the future Durga P. Bubba Head, Alliance Management, Merck Vaccines and Infectious Diseases Durga Bobba joined Merck in 1996 and has worked in US pharmaceutical marketing, business development and international vaccine marketing. He has experience in executing the deal and making it work in a global organization. He is currently the head of Alliance Management for the Merck Vaccines Division which includes responsibility of 6 vaccine alliances on 4 continents. Two of the six alliances ge [read more] Mike Leonetti Executive Director, Alliance Management, Boehringer-Ingelheim An accomplished Pharmaceutical Executive with 20 years of successful experience in a variety of key leadership capacities demonstrating diverse leadership skills to develop highly visible Health Care alliances resulting in multi billion dollar partnerships. As a long time employee with Boehringer Ingelheim, Mike has led multiple commercial functions including: Health Care Partnerships, Government [read more] Stefanie A. Hansen Director, Pharmaceutical Strategic Alliances Worldwide Business Development, Pfizer Stefanie A. Hansen, JD is a Director in World Wide Business Development at Pfizer Inc. and is responsible for the design, implementation and management of a strategic portfolio of external investments which advances strategies and creates a sustainable competitive advantage. The portfolio spans the entire range of discovery and development activities, from gene and target discovery to enhancing th [read more]

11:45 - Partnering With Roche And Genentech: New Opportunities For Innovation Sarah Holland, Head, CNS Partnering, Roche Suzy Jones, Senior Director, Business Development, Genentech Carole Nuechterlein, Head, Roche Venture Fund In 2009, Roche and Genentech merged but Roche Pharma Partnering and Genentech Business Development have remained independent of each other and the Roche Venture Fund is independent of both. The business development groups have very different structures. Yet these three groups have built a close working relationship. Obtain insight from how these three groups work together to assess opportunities and do deals and how you can best interact with them. How biotechs should approach Roche and Genentech in business development. How does the Roche Venture Fund interact with the two business development groups? What has each party learned from each as they work together? Sarah Holland Head, CNS Partnering, Roche Sarah Holland is the CNS therapy area lead for Roche Pharma Partnering, based in Basel, Switzerland. Since joining Roche in 2005, Sarah has been responsible for evaluating licensing opportunities in a range of disease areas, including the Plexxikon deal on b-raf inhibitors, the Memory deal on Nicotinic alpha-7 agonists and the Evotec deal on NR2B NMDA antagonists. Prior to joining Roche, Sarah was [read more] Suzy Jones Senior Director, Business Development, Genentech Suzy Jones is Senior Director of Business Development at Genentech. Her group is responsible for identifying new external opportunities that will support the company’s short- and long-term business objectives and negotiating collaboration agreements to support the newly formed strategic alliances. Suzy’s career includes 19 years of biotech experience. She spent 7 years conducting basic immunology [read more] Carole Nuechterlein Head, Roche Venture Fund Carole Nuechterlein has headed the Roche Venture Fund since 2001. Prior to her current position, she worked in the pharmaceutical/biotech as an attorney for ten years. She joined Roche from SangStat in Fremont California where she was General Counsel. Carole began her career working at Skadden Arps Slate Meagher & Flom in the M&A group. From there, she worked at Syntex/Roche in Palo Alto, [read more]

12:25 - PANEL: Re-Engaging Potential Partners: How To Get Them To Take A Second Look Matthew Meyer, Vice President Business Development and Licensing, Cerimon Remis Bistras, VP Business Development, EyeGate Pharma Ed Baracchini, SVP Business Development, Metabasis Therapeutics It’s clear that there are only so many viable compounds being developed. Not surprisingly, Pharma executives are aware that the developers of these attractive compounds are being courted by every major company in the industry. But what do you do if you’ve been turned down? How do you re-engage and get these companies to see the value in your compound? Understanding exactly the kinds of data that will interest potential partners Articulating how your program falls within their strategic direction Collaborating with potential partners to design a path where your product could align with their strategy in the future Matthew Meyer Vice President Business Development and Licensing, Cerimon Matthew Meyer is the General Counsel and Vice President of Business Development and Licensing. Mr. Meyer has 15 years’ experience in commercial law, business development, marketing and licensing with large pharmaceutical, medical device and early stage healthcare companies in the US and Europe. Before joining Cerimon, Mr. Meyer served as Vice President and General Counsel at Draeger Medical System [read more] Remis Bistras VP Business Development, EyeGate Pharma Remis Bistras, Ph.D., Vice President, Business Development, is leading EyeGate worldwide business development and licensing activities. Remis Bistras was formerly Director of Business Development & Licensing at CIBA Vision, a division of Novartis, where he was responsible for managing worldwide business development and licensing in the eye care area. In addition, Remis managed a clinical trial [read more] Ed Baracchini SVP Business Development, Metabasis Therapeutics Edgardo Baracchini, Ph.D., M.B.A., Senior Vice President of Business Development - Dr. Baracchini has been the head of business development at Metabasis Therapeutics since May 2002. Initially he was the Vice President of Business Development and in April 2005 was promoted to Senior Vice President of Business Development. Dr. Baracchini has over 15 years' experience in structuring and negotiating r [read more]

1:05 - Lunch For All Conference Attendees Lunch For All Conference Attendees Sponsored by:

2:15 - Track A: IN-DEPTH: Lessons On Evolving IP Alison Shurell, VP of Life Sciences Product Marketing, Intralinks Chairperson’s Remarks Alison Shurell VP of Life Sciences Product Marketing, Intralinks Alison Shurell is vice president of Life Sciences Product Marketing. She is responsible for building on IntraLinks position as the leading software as a service solution for critical information exchange in the Life Sciences industry. In this role, she partners with industry leaders in corporate development, clinical studies and regulatory affairs to help ensure the secure and efficient exchange o [read more] 2:15 - Track B: IN-DEPTH: Lessons In Maximizing BD Opportunities Jacob Licht, Director of Corporate Development, Emergent BioSolutions Chairperson’s Remarks Jacob Licht Director of Corporate Development, Emergent BioSolutions As Director of Corporate Development at Emergent BioSolutions in Rockville, MD, Jacob’s responsibilities include overseeing strategic planning; identifying and evaluating licensing and acquisition opportunities; and negotiating transactions. Since joining Emergent Jacob has identified and negotiated several transactions supporting the company’s biodefense and commercial efforts. Prior to joining E [read more]

Track A: IN-DEPTH: Lessons On Evolving IPTrack B: IN-DEPTH: Lessons In Maximizing BD Opportunitie... 2:25 - PANEL: Understanding The Implications Of KSR On The Pharmaceutical/Biotech Industry Track A: IN-DEPTH: Lessons On Evolving IP John Li, Head, Intellectual Property, Novartis Biologics, Novartis Len Smith, Senior Intellectual Property Counsel, Novo Nordisk With the Supreme Court’s decision on KSR, a precedent on obviousness was made, arguably making patent infringement much more of a reality. This comes at a particularly bad time, as most Big Pharma are struggling to maintain the validity of their patents on some of their most successful compounds. Evaluating the current legal situation to understand how the judicial system is reacting to KSR and the obviousness ruling Addressing how these topics affect current partnership strategies and collaborations, as well as deals and valuations Examining strategies to protect your intellectual property assets given the implications of KSR John Li Head, Intellectual Property, Novartis Biologics, Novartis John Li is the Head of Biology and Biologics in NIBR Patents, a role that includes coordination and quality control of biologics patenting and freedom-to-operate analysis across all disease areas, platforms, and functions within NIBR. John joined NIBR as a US patent attorney in September 2006 from Therion Biologics Corp., where he served as Director of Intellectual Property. Prior to joining Theri [read more] Len Smith Senior Intellectual Property Counsel, Novo Nordisk Len holds a Juris Doctor from Washington University in St. Louis, Missouri, a Bachelor of Science in Biology from the University of Missouri, and a Masters of Environmental Science from Southern Illinois University. He is currently working towards obtaining additional graduate degrees in Bioinformatics and Information Sciences. Prior to joining Novo Nordisk in August 2003, Len was an associate wit [read more] 2:25 - PANEL: Developing A Strategy For Financing Early Research: Working With Academia Track B: IN-DEPTH: Lessons In Maximizing BD Opportunities Ian Mehr, Managing Director, Golden Pine Ventures Grace Yee, Licensing Officer, University of California, Irvine Rich Christie, VP, Business Development, Johnson and Johnson Doug Fisher, Principal, InterWest Partners R&D budget cuts and lack of access to capital has resulted in a serious decline in viable late stage assets. As a result, more and more big Pharmas and big biotechs are looking at pre-clinical and very early development assets. With this new area of potential partners comes a new set of potential challenges and questions. Understanding the legal implications of licensing from an academic institution Evaluating how “pipelining” could affect the ultimate terms of the partnerships Minimizing the risk of partnering with such an early stage asset Ian Mehr Managing Director, Golden Pine Ventures Dr. Mehr's extensive experience in the life sciences spans both research and business development. Prior to joining Golden Pine Ventures Dr. Mehr served as Vice President of Business Development for Qualyst, Inc., a privately-held biotechnology company focused on novel and proprietary products that increase the efficiency and effectiveness of drug discovery and development. Dr. Mehr has also led b [read more] Grace Yee Licensing Officer, University of California, Irvine Grace Yee is a licensing officer from the University of California, Irvine. She is responsible for a portfolio of technologies related to medical devices and life sciences. Grace interfaces on behalf of University researchers with industrial partners in the areas of licensing, sponsored research, and other forms of academic and industrial partnerships. Prior to the University of California, Grace [read more] Rich Christie VP, Business Development, Johnson and Johnson Doug Fisher Principal, InterWest Partners Prior to joining InterWest, Dr. Fisher was a vice president at New Leaf Venture Partners where he spent three years focusing on biopharmaceutical, medical device, and diagnostics investments. He was involved with several investments, including: Pearl Therapeutics, Access Closure, and GluMetrics. Prior to joining New Leaf, Dr. Fisher was a project leader with The Boston Consulting Group where he wa [read more]

Track A: IN-DEPTH: Lessons On Evolving IPTrack B: IN-DEPTH: Lessons In Maximizing BD Opportunitie... 3:05 - PANEL: Defining Legal & Regulatory Challenges On BioSimilars Track A: IN-DEPTH: Lessons On Evolving IP Mark Bowditch, Sr Biotech IP Attorney, Sandoz Kerry Flynn, Vice President, Intellectual Property, Shire The question still remains: Can a biological product be replicated in a safe and effective manner given its complex nature? As Congress prepares to pass new legislation on biosimilars, the questions surfacing about these patents have become much more pressing. Characterizing the challenges surrounding the new follow-on legislation and how both Pharma and generic companies could be affected Understanding the implications of the new PTO rules on biologics and biosimilars patent applications Addressing patent prosecution issues such as inequitable conduct and the consequences of complying with the new PTO rules Mark Bowditch Sr Biotech IP Attorney, Sandoz Mark Bowditch is an attorney with Sandoz Inc., specializing in intellectual property law. He is responsible for all intellectual property matters for Sandoz's U.S. biopharmaceuticals division. Mr. Bowditch has a Master of Science degree in Biology, a law degree from the George Washington University National Law Center, and over 25 years experience in the fields of generic drug, biotechnology, and [read more] Kerry Flynn Vice President, Intellectual Property, Shire Kerry Flynn is Vice President for Intellectual Property at Shire. She has over 20 years of experience in the Intellectual Property and Licensing field, and has recently earned the newly released designation of Certified Licensing Professional from the Licensing Executives Society. Ms. Flynn was previously Vice President of Business Development and Intellectual Property at Transkaryotic Therapies, [read more] 3:05 - Case Study: Novartis And Portola – Win-Win Pharma-Biotech Collaborations Are Still Getting Done Despite Challenging Times Track B: IN-DEPTH: Lessons In Maximizing BD Opportunities William Lis, Chief Operating Officer, Portola Pharmaceuticals Markus L.E. Ewert, PhD MBA, Molecular Diagnostics, Global Head of Strategy, BD&L, and M&A, Novartis Pharma AG In 2008 industry analysts predicted that a series of unhealthy deals between big Pharma and biotech would be triggered by either biotech’s inability to independently finance operations during the economic crisis or due to Big Pharma’s desperation to fill the paucity in its R&D pipelines. True to predictions, in many recent deals, biotechs have settled for terms that significantly undervalued their assets and capabilities and likewise, in several high profile collaborations, Pharma has significantly over-paid for long-shot compounds. However, Pharma – Biotech collaborations resulting in balanced economics and collaborative structures benefiting both parties are still getting done. A case in point: Novartis’ global license of Portola’s intravenous and oral anti-platelet agent Elinogrel, a potential blockbuster in the world-wide $17 billion thrombosis market. Both sides will present the long road to negotiating a deal that currently looks to be a win-win for both parties. William Lis Chief Operating Officer, Portola Pharmaceuticals Bill Lis has over 18 years of experience in biopharmaceutical and medical device sales & marketing, business development, and management. Currently he is Sr Vice President Business and Commercial Development, Portola Pharmaceuticals and is a member of the executive management team. His team recently executed a global license agreement for Portola’s Phase II antiplatelet agent Elinogrel with No [read more] Markus L.E. Ewert, PhD MBA Molecular Diagnostics, Global Head of Strategy, BD&L, and M&A, Novartis Pharma AG Markus L.E. Ewert is member of the Novartis Molecular Diagnostics leadership team and leading the strategy, global BD&L, and M&A activities. Prior to joining MDx, he was member of the CVM Franchise Board at Novartis Pharma AG and served as Global Head Search & Evaluation for cardiovascular and metabolic diseases. Markus earned a PhD in molecular biology in Heidelberg in 1991 and an MBA [read more]

3:45 - Refreshment Break And Networking Opportunity Refreshment Break And Networking Opportunity

Track A: IN-DEPTH: Lessons On Evolving IPTrack B: IN-DEPTH: Lessons In Maximizing BD Opportunitie... 4:20 - PANEL: Understanding The Implications Of Bilski On The Diagnostics Business Models Track A: IN-DEPTH: Lessons On Evolving IP Patrick Farley, Senior Patent Counsel, Genentech Luisa Bigornia, Vice President, Intellectual Property, BioMarin Pharmaceuticals In recent years, the buzz around personalized medicine has grown exponentially. No longer to be ignored, the diagnostics industry promises to provide a wealth of new treatments options. However, Bilski and its subsequent cases are causing a stir, challenging the validity of genetic testing patents and potentially creating a serious hurdle for the continued success of this industry. Defining the term “natural phenomenon” and its interpretations Outlining strategies for the prosecution of the Bilski/Classen/Prometheus issue Understanding under what grounds a biotech’s claims should be challenged under under §101 Patrick Farley Senior Patent Counsel, Genentech Luisa Bigornia Vice President, Intellectual Property, BioMarin Pharmaceuticals Dr. Bigornia joined BioMarin Pharmaceutical Inc. in February 2003 and currently serves as the Vice President of Intellectual Property (IP). She is responsible for the management of all company IP matters, the development and implementation of patent strategy for all company programs, and the provision of IP-related support to Business Development, Commercial Planning, Regulatory, Clinical, Researc [read more] 4:20 - PANEL: Finding Viable Partnership Opportunities In The Precarious World Of Psychiatry & CNS Track B: IN-DEPTH: Lessons In Maximizing BD Opportunities Sarah Holland, Head, CNS Partnering, Roche Jeffrey Brennan, VP Business Development, Targacept Every therapeutic area claims its own particular challenges, but nowhere is this truer than in the CNS space. With poor (if any) correlation between animal models and human responses, very few compounds survive clinical trials. As a result, only a handful of targets are currently being evaluated, leaving partnering opportunities for those companies forging ahead in this therapeutic area. Determining deal structures that are aligned with the specific risks associated with CNS partnering Finding new opportunities in this very small community and reassessing programs as they progress Supporting early-stage and academic research to enable new scientific breakthroughs to address unmet medical needs in this therapeutic area Sarah Holland Head, CNS Partnering, Roche Sarah Holland is the CNS therapy area lead for Roche Pharma Partnering, based in Basel, Switzerland. Since joining Roche in 2005, Sarah has been responsible for evaluating licensing opportunities in a range of disease areas, including the Plexxikon deal on b-raf inhibitors, the Memory deal on Nicotinic alpha-7 agonists and the Evotec deal on NR2B NMDA antagonists. Prior to joining Roche, Sarah was [read more] Jeffrey Brennan VP Business Development, Targacept

5:00 - Cocktail Reception Sponsored by: At BioNetwork we give you every opportunity to network. The cocktail receptions are your chance to cement the relationships you have been building through the day with a stiff drink and some delicious nibbles. It’s time to loosen up, enjoy yourself, while still continuing to network